Sunday, 4 October 2026European Markets

ABC ARBITRAGE And 1 Other Stocks Have Very High Payout Ratio

Loading stream...

(VIANEWS) - ABC ARBITRAGE (ABCA.PA), IRISH RES. PROP. (IRES.IR), () are the highest payout ratio stocks on this list.

We have congregated information regarding stocks with the highest payout ratio as yet. The payout ratio in itself isn't a promise of good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.

1. ABC ARBITRAGE (ABCA.PA)

128.89% Payout Ratio

ABC arbitrage SA, together with its subsidiaries, develops arbitrage strategies for liquid assets worldwide. It develops liquidity, statistical, risk, and derivatives arbitrage strategies; and provides asset and portfolio management services. The company was incorporated in 1995 and is based in Paris, France.

Earnings Per Share

As for profitability, ABC ARBITRAGE has a trailing twelve months EPS of €0.6.

PE Ratio

ABC ARBITRAGE has a trailing twelve months price to earnings ratio of 10.36. Meaning, the purchaser of the share is investing €10.36 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.35%.

2. IRISH RES. PROP. (IRES.IR)

50.34% Payout Ratio

Irish Residential Properties REIT Plc (“I•RES” registration # 529737) is an Irish REIT focused on consolidating the fragmented Irish rental market by targeting quality multi-unit residential real estate in Dublin and other major centres. I•RES is externally managed by certain subsidiaries of CAPREIT (TSX:CAR.UN). Through its arrangements with CAPREIT, I•RES's operational strategy is to deliver superior customer service, enhance tenant retention, and deliver quality homes by leveraging CAPREIT's hands-on experience, and proven operating philosophies. I•RES was listed on the Irish Stock Exchange (now Euronext Dublin) in April 2014.

Earnings Per Share

As for profitability, IRISH RES. PROP. has a trailing twelve months EPS of €0.111.

PE Ratio

IRISH RES. PROP. has a trailing twelve months price to earnings ratio of 8.77. Meaning, the purchaser of the share is investing €8.77 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -1.37%.

Yearly Top and Bottom Value

IRISH RES. PROP.'s stock is valued at €0.97 at 21:10 EST, below its 52-week low of €1.04.

Volume

Today's last reported volume for IRISH RES. PROP. is 935731 which is 12.32% above its average volume of 833093.

Sales Growth

IRISH RES. PROP.'s sales growth for the current quarter is negative 4.2%.

Moving Average

IRISH RES. PROP.'s worth is way under its 50-day moving average of €1.13 and way under its 200-day moving average of €1.20.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com